Trials / Recruiting
RecruitingNCT05873686
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Nuvectis Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.
Conditions
- Advanced Solid Tumor
- NSCLC (Non-small Cell Lung Cancer)
- Renal Cancer
- Mesothelioma
- Non-Small Cell Squamous Lung Cancer
- Non-small Cell Lung Adenocarcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NXP900 | NXP900 is an orally administered SRC/YES1 kinase inhibitor |
Timeline
- Start date
- 2023-10-26
- Primary completion
- 2027-03-01
- Completion
- 2027-07-01
- First posted
- 2023-05-24
- Last updated
- 2026-03-03
Locations
12 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05873686. Inclusion in this directory is not an endorsement.